SCHEMBL23200344

SCHEMBL23200344

COC(=O)c1cc2ccccc2cc1NS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.64
CYP2C9 P11712 4/20 0.58
CYP2C19 P33261 2/20 0.58
LMNA P02545 6/20 0.56
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
CYP1A2 P05177 1/20 0.55
TCF4 P15884 1/20 0.54
CTNNB1 P35222 1/20 0.54
MCL1 Q07820 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
TSHR P16473 2/20 0.52
MAPT P10636 3/20 0.51
ALDH1A1 P00352 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KEAP1 Q14145 2/20 0.51
USP2 O75604 1/20 0.51
POLB P06746 1/20 0.51
NOD2 Q9HC29 1/20 0.51
NFE2L2 Q16236 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31138226 1.00 FFAR4 (0.64) FFAR4CYP2C9CYP2C19LMNAMEN1
SCHEMBL23200358 0.86 METAP2 (0.68) CYP2C9CYP2C19LMNAMEN1KMT2A
SCHEMBL1495939 0.83 FFAR4 (0.80) FFAR4CYP2C9CYP2C19LMNAMEN1
SCHEMBL7571483 0.83 LMNA (0.67) CYP2C9CYP2C19LMNAMEN1KMT2A
SCHEMBL31123649 0.83 KDM4E (0.63) FFAR4CYP2C9CYP2C19LMNAMEN1
SCHEMBL22451555 0.82 LMNA (0.62) FFAR4CYP2C9CYP2C19LMNAMEN1
SCHEMBL31138312 0.82 FFAR4 (0.65) FFAR4CYP2C9CYP2C19LMNAMEN1
SCHEMBL23200363 0.82 FFAR4 (0.65) FFAR4CYP2C9CYP2C19LMNAMEN1
SCHEMBL3512980 0.82 CYP2C9 (0.72) FFAR4CYP2C9CYP2C19LMNAMEN1
SCHEMBL3511869 0.80 FFAR4 (0.62) FFAR4CYP2C9LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 EP disclosed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 EP disclosed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 US disclosed
EP-3802514-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2022-08-03 EP disclosed
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2022-07-19 US disclosed
EP-3802514-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES LUC7L2, LYPLAL1, GUSB FFAR4 4152/4885CYP2C9 1823/4885CYP2C19 2244/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB FFAR4 4152/4885CYP2C9 1823/4885CYP2C19 2244/4885
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB FFAR4 4152/4885CYP2C9 1823/4885CYP2C19 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.